Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evguenia Ouchveridze

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Hematologic Malignancy Reports|August 30, 2022
Value in Myeloma Care: Myth or RealityEvguenia Ouchveridze, Katherine Berger, Ghulam Rehman Mohyuddin
Cancers|October 14, 2023
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple MyelomaAimaz Afrough, Shebli Atrash, Barry Paul, et al.
Blood Cancer Journal|April 23, 2022
Financial toxicity in hematological malignancies: a systematic reviewEvguenia Ouchveridze, Rahul Banerjee, Aakash Desai, et al.
European Journal of Haematology|January 16, 2026
Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter StudyRazan Mansour, Kimberly M Green, Chandler Graf, et al.
American Journal of Hematology|June 5, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter studyAung M Tun, Romil D Patel, Frederique St-Pierre, et al.
Blood Cancer Journal|June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumDanai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood Advances|April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal ImpairmentDanai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Hematologic Malignancy Reports|August 30, 2022
Value in Myeloma Care: Myth or RealityEvguenia Ouchveridze, Katherine Berger, Ghulam Rehman Mohyuddin
Cancers|October 14, 2023
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple MyelomaAimaz Afrough, Shebli Atrash, Barry Paul, et al.
Blood Cancer Journal|April 23, 2022
Financial toxicity in hematological malignancies: a systematic reviewEvguenia Ouchveridze, Rahul Banerjee, Aakash Desai, et al.
European Journal of Haematology|January 16, 2026
Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter StudyRazan Mansour, Kimberly M Green, Chandler Graf, et al.
American Journal of Hematology|June 5, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter studyAung M Tun, Romil D Patel, Frederique St-Pierre, et al.
Blood Cancer Journal|June 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumDanai Dima, Mariola A Vazquez-Martinez, James A Davis, et al.
Blood Advances|April 8, 2025
Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal ImpairmentDanai Dima, Aimaz Afrough, Utkarsh Goel, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 2